PMC8596653_01
Plasma concentrations of remdesivir and GS-441524. (A) Plasma concentrations of remdesivir and GS-441524 during the remdesivir administration period. () Remdesivir 200 mg administered in 1 h, () Remdesivir 100 mg administered in 1 h. (B) The plasma concentrations of remdesivir and GS-441524 4 h after administration (C4) on day 17 were 662 ng/mL and 58 ng/mL, respectively. However, the concentrations of remdesivir and GS-441524 18 h after administration (C18) were 32 ng/mL and 44 ng/mL, respectively. The peak values of remdesivir and GS-441524 were calculated to be 1576 ng/mL and 63 ng/mL, respectively, and the trough values were calculated to be 11 ng/mL and 40 ng/mL, respectively. The following formulas were used to calculate the values. The half-life (hr) = T1/2 = ln2 x (1/kel) = ln2 x (TC18-TC4)/(lnC4-lnC18). The peak value (ng/mL) = C0 = C4 x 2^{(TC4-TC0)/(T1/2)}. The trough value (ng/mL) = C23 = C18 x (1/2)^{(TC23-TC18)/(T1/2)}. Kel: elimination rate constant (hr-1), T: time of blood sampling.
gr1.jpg
PMC8596653_01_gr1.jpg
fig0005
Veno-venous ECMO with silicone-coated polypropylene membranes was implemented on day 8 via the right femoral vein for blood drainage and the right internal jugular vein for blood return.(Fig. 1).